本文へ移動
cccskills
無料GitHub で公開

medication-induced-hypercalcemia-screener

Screen a hypercalcemic patient for medication- and supplement-induced causes — thiazides, lithium, vitamin D, vitamin A/retinoids, antiestrogens, theophylline, milk-alkali, SGLT2 inhibitors, immune checkpoint inhibitors, denosumab rebound, teriparatide/abaloparatide, foscarnet, ketogenic diet, aluminium. Trigger when a clinician asks "is this hypercalcemia drug-induced", "thiazide hypercalcemia", "lithium hypercalcemia", "denosumab rebound hypercalcemia", "vitamin D toxicity", "milk-alkali syndrome", "SGLT2 hypercalcemia", or any new hypercalcemia where medication review is needed.

dromlakhani/MD2SKILL
インストール方法を見る

含まれるファイル（1）

  • SKILL.md6.1 KB

SKILL.md（原文）

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Medication-Induced Hypercalcemia — Screener

Run this skill on every new hypercalcemic patient before diagnosing PHPT or MAH. Drug- and supplement-induced hypercalcemia is reversible and easily missed.

STEP 1 — Take the medication & supplement history

Ask explicitly about:

  • Prescription drugs — diuretics, mood stabilisers, oncology drugs, antivirals, osteoporosis injections
  • OTC supplements — vitamin D, vitamin A, calcium, multivitamins, "bone health" preparations
  • Antacids — calcium carbonate, milk-of-magnesia
  • Recent injections — denosumab, teriparatide, abaloparatide, ICIs
  • Recently stopped — denosumab discontinuation can cause rebound hypercalcemia
  • Diet — ketogenic diet, large dairy intake, large vitamin D supplementation

STEP 2 — Match to the agent and act

Group A — Diuretics & mood stabilisers (PTH-dependent picture, mimics PHPT)

Thiazides

  • Reduces renal Ca clearance. Typically only causes hypercalcemia in pre-existing PHPT or anephric patients.
  • Action: stop the thiazide. Recheck Ca in 1–2 weeks. If still elevated → workup for PHPT.

Lithium

  • 5% of users develop hypercalcemia. Shifts CaSR set-point upward + reduces renal Ca clearance.
  • Action: stop or switch lithium if clinically possible (psychiatric collaboration). If lithium must continue and Ca is sustained high → consider PHPT workup; cinacalcet may be useful.

Group B — Vitamin / mineral excess

Vitamin D (D2, D3, 25(OH)D, calcitriol)

  • Long half-life of cholecalciferol → hypercalcemia can persist weeks to months.
  • Action: stop vitamin D. Hydration, calciuresis. Glucocorticoids + antiresorptive if severe. Restrict dietary calcium. Avoid sun.

Vitamin A / retinoids (cis-retinoic acid, ATRA) — >50,000 IU/day

  • Mechanism: enhanced bone resorption.
  • Action: stop, hydrate, antiresorptive if severe.

Milk-alkali syndrome — Ca carbonate ≥3 g/d + alkali (often modern OTC use)

  • Triad: hypercalcemia + metabolic alkalosis + AKI / nephrocalcinosis.
  • Action: stop calcium and antacid, rehydrate. Hemodialysis rarely.

Group C — Antiresorptive / anabolic bone agents

Denosumab — rebound hypercalcemia after discontinuation

  • Most cases: children with bone tumours / fibrous dysplasia, occasionally adults with osteoporosis.
  • Action: do not stop denosumab abruptly without bridging (bisphosphonate). If rebound has occurred → IV bisphosphonate, hydration.

Teriparatide [PTH(1-34)] / Abaloparatide [PTHrP analog]

  • Transient hypercalcemia post-injection, resolves ~16 h.
  • Action: confirm timing. If sustained → stop and reassess.

Group D — Oncology / antiviral / metabolic drugs

Antiestrogens (tamoxifen) — "tumour flare" hypercalcemia in breast cancer with bone mets

  • Self-limiting; may need acute treatment (hydration, antiresorptive).

Theophylline / aminophylline

  • Reversible on stopping; β-blockers can also help.

Foscarnet (antiviral, CMV)

  • Rare; reversible on cessation.

Aluminum intoxication

  • Setting: CKD on aluminium-containing phosphate binders, or contaminated dialysate / TPN.
  • Action: stop aluminium source; chelate with desferrioxamine.

SGLT2 inhibitors

  • Mechanism: osmotic diuresis + volume contraction, especially with co-existing risk factors (dehydration, thiazide, acidosis, undiagnosed PHPT).
  • Action: hold drug, rehydrate, screen for PHPT.

Immune checkpoint inhibitors (ICIs)

  • Mechanisms: ICI-induced hyperthyroidism / adrenal insufficiency / sarcoid-like granulomatosis / PTHrP / hyperprogression.
  • Action: full workup including TSH, cortisol, PTHrP, imaging for new granulomas. Manage cause-specifically; glucocorticoids if granulomatous or adrenal.

Ketogenic diet (children with epilepsy)

  • Mechanism: impaired osteoblast activity, reduced bone formation.
  • Action: dietitian review; consider modifying ratio.

STEP 3 — Confirm reversibility

After stopping the suspected agent:

  • Recheck corrected calcium at 1–2 weeks (longer for vitamin D — up to 8 weeks).
  • If calcium normalises → diagnosis confirmed.
  • If calcium remains elevated → return to the hypercalcemia-diagnostic-algorithm for PHPT, FHH, or MAH workup.

CLINICAL GUARDRAILS

  • Drug-induced hypercalcemia can coexist with PHPT. Thiazide and lithium often unmask mild PHPT — recheck calcium after a 2–4 week washout before booking surgery.
  • Vitamin D toxicity is long-lived. Cholecalciferol persists for weeks-to-months. Do not assume rapid resolution.
  • Don't abruptly stop denosumab. Bridge with a bisphosphonate to prevent rebound resorption and hypercalcemia (especially in patients with high bone turnover).
  • Lithium can't always be stopped. Coordinate with psychiatry; cinacalcet is an option in lithium-induced hypercalcemia who must continue lithium.
  • OTC supplement load is often hidden. Ask about gummies, "bone-health" multivitamins, fish liver oil. Patients don't always volunteer these.
  • ICIs cause endocrine mimics. A patient on pembrolizumab/nivolumab with hypercalcemia needs TSH, cortisol, ACTH, and chest imaging — not just a calcium recheck.

SOURCE

Bilezikian JP, Endotext. Approach to Hypercalcemia. NCBI Bookshelf NBK279129. Section: Medication-Induced Hypercalcemia (Thiazides, Lithium, Vitamin D, Vitamin A, Antiestrogens, Theophylline, Aluminum, Milk-Alkali, SGLT2i, ICIs, Denosumab, Teriparatide/Abaloparatide, Foscarnet, Ketogenic diet).

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

ログインしてレビューを書く

同じリポジトリのスキル

概要と使いどころ

780g-pump-adjustment

無料

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-acth-stim-test-interpretation

無料

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-adrenal-crisis-treatment

無料

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-ai-education

無料

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-lt4-monitoring

無料

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-cortisol-cutoff-ai-diagnosis

無料

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する